An economic evaluation of topical treatments for actinic keratosis

Journal of Dermatological Treatment

Volumn 20, Issue 5, 2009, Pages 266-275

  Muston, Dominic ^a   Downs, Anthony ^b   Rives, Vincent ^c  

^a Heron Evidence Development Ltd   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c Galderma R and D   (France)

Author keywords

5 fluorouracil; Actinic keratosis; Cost effectiveness; Decision tree; Imiquimod; MAL PDT

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD;

ACTINIC KERATOSIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CRYOTHERAPY; CURETTAGE; DECISION TREE; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; ELECTROSURGERY; EXCISION; HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SUN EXPOSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM;

ADMINISTRATION, CUTANEOUS; AMINOLEVULINIC ACID; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; FLUOROURACIL; GREAT BRITAIN; HUMANS; KERATOSIS, ACTINIC; MODELS, ECONOMIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 75849137369     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630902887211     Document Type: Article

References (41)

1. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:(1 Pt 2)4-7.
2. Marks R. An overview of skin cancers. Incidence and causation. Cancer. 1995;75:(2 suppl)607-12.
3. Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: A clinical-histopathologic correlation. Dermatol Surg. 2006;32:1261-5.
4. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142:1154-9.
5. Harvey I, Frankel S, Marks R, Shalom D, Nolan-farrell M. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer. 1996;74:1302-7.
6. . De Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222-30.
7. Morton CA, Brown SB, Collins S, Ibbotson S, Jenkinson H, Kurwa H, et al. Guidelines for topical photodynamic therapy: Report of a workshop of the British Photodermatology Group. Br J Dermatol. 2002;146:552-67.
8. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ. 1999;319:635-8.
9. Mcintyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am Fam Physician. 2007;76:667-71.
10. Tarstedt M. A multicentre, phase III, randomised study of photodynamic therapy (PDt) with Metvix® 160 mg/g cream comparing two treatment regimens in patients with actinic keratosis. Oslo: Photocure ASA; 24 June 2003. Report No.: PCT311/01.
11. Foley P. A multicentre, phase III, randomised study of photo-dynamic therapy (PDT) with Metvix® 160 mg/g cream in comparison with cryotherapy and PDT with placebo cream in patients with actinic keratosis. Oslo: Photocure ASA; 25 Jan 2001. Report No.: PCT305/99.
12. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85:424-8.
13. Alomar A, Bichel J, Mcrae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133-41.
14. Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007;57:265-8.
15. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990-1000.
16. Krawtchenko N, Roewert-huber J, Ulrich M, Mann I, Sterry W, Stockfeth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157:(suppl 2)34-40.
17. Tanghetti E, , Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol. 2007;6:144-7.
18. British National Formulary. 11 September 2008 [cited 2008 Nov 28]; 56. URL: http://www.bnf.org
19. Perrett CM, Mcgregor JM, Warwick J, Karran P, Leigh IM, Proby CM, et al. Treatment of post-transplant premalignant skin disease: A randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007;156:320-8.
20. Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: A prospective, randomized study. J Dermatolog Treat. 2003;14:99-106.
21. Rives V, Sarkany M. Management of superfcial basal cell carcinoma (sBCC) with METVIX® (MAL-PDT) in real life practice in the Belgian population. 16th Congress of the European Academy of Dermatology and Venereology; 2007 Vienna, Austria.
22. Galderma Watford, Hertfordshire, UK Ltd. Summary of product characteristics: Metvix. Dec 2005.
23. Meda Pharmaceuticals, Takeley, Bishop's Stortford, UK. Summary of product characteristics: Aldara 5% cream. 17 February 2009.
24. Valeant Pharmaceuticals Ltd, Basingstoke, Hampshire, UK. Summary of product characteristics: Efudix. Apr 2005.
25. NHS. Reference costs 2002/3. 5 February 2004. URL: http://www.dh.gov.uk/ PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/ PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT-ID=4070195&chk=UzhHA3.
26. NHS. Reference costs 2006/7. January 2008. URL: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-074072.
27. Curtis LaNA. Unit costs of health and social care 2007. URL: http://www.pssru.ac.uk/pdf/uc/uc2007/uc2007.pdf.
28. UCSHC 2007. Inflation indices; 2007: 185-6. URL: http://www.pssru.ac.uk/ pdf/uc/uc2007/uc2007-inflationindices
29. Haymarket Group. eMIMS. 17 January 2008. URL: http://www. healthcarerepublic.com/
30. Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate- photodynamic therapy and cryotherapy in subjects with actinic keratoses: A multicentre, randomized controlled study. Br J Dermatol. 2006;155:1029-36.
31. Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics. 2004;22:83-94.
32. Caekelbergh K, Annemans L, Lambert J, Roelandts R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol. 2006;155:784-90.
33. Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol. 2003;149: (suppl 66)31-3.
34. Drummond MF. The future of pharmacoeconomics: Bridging science and practice. Clin Ther. 1996;18:969-78.
35. Ellis CN, Reiter KL, Wheeler JR, Fendrick AM. Economic analysis in dermatology. J Am Acad Dermatol. 2002;46:271-83.
36. Campbell DT. Stanley JC. Experimental and Quasi-Experimental Designs for Research. Chicago: Rand McNally. 1963.
37. Annemans L, Caekelbergh K, Roelandts R, Boonen H, Leys C, Nikkels A, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoms. Eur J Dermatol 2008; 18(5):539-546.
38. Hodari KT, Nanton JR, Carroll CL, Feldman SR, Balkrishnan R. Adherence in dermatology: A review of the last 20 years. J Dermatolog Treat. 2006;17:136-42.
39. Spencer JM, Hazan C, Hsiung SH, Robins P. Therapeutic decision-making in the therapy of actinic keratoses. J Drugs Dermatol. 2005;4:296-301.
40. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: A review and case studies. Health technol Assess. 2004;8:iii-192.
41. Claxton K, Sculpher M, Mccabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: Not an optional extra. Health Econ. 2005;14:339-47.